International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel
NCT02051868
Unknown
Anal cancer is a relatively uncommon disease and there is currently no standard chemotherapy treatment for patients with inoperable locally recurrent or metastatic disease. The aim of this phase II study is compare two well known and largely used chemotherapy regimens - Cisplatin plus 5-fluorouracil vs Carboplatin plus Paclitaxel. The result of this study will set a standard of care for this disease and provide useful information for future Phase III trials.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2015
Locations: Laura Gagnon, Boston, Massachusetts +2 locations
Conditions: Squamous Cell Carcinoma of the Anus
Register for Updates
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
NCT00059787
Completed
This phase II trial is studying the side effects of giving erlotinib together with carboplatin and paclitaxel and to see how well it works in treating patients with stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy such as carboplatin and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or d... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/29/2015
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Register for Updates
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
NCT00588094
Completed
The purpose of this research is to study a treatment program for patients with aggressive lymphoma that has come back after initial or first therapy (called relapsed) or that has not responded to first therapy (called refractory). Since 1993, we have used a combination of chemotherapy known as ICE (Ifosfamide, Carboplatin, and Etoposide) for your type of lymphoma. In many patients, this treatment helps the disease to shrink before giving high-dose therapy and autologous stem cell transplant (ASC... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
10/27/2015
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Lymphoma, B-cell Non-Hodgkin's Lymphoma
Register for Updates
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel
NCT00768131
Withdrawn
The purpose of this study is to determine if EGFR status (positive or negative) by FISH can predict response to cetuximab therapy in NSCLC patients treated with carboplatin and paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2015
Locations: Local Institution, Little Rock, Arkansas +13 locations
Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Register for Updates
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
NCT00043082
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without liposomal doxorubicin in treating recurrent ovarian epithelial or primary peritoneal cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of carboplatin with or without liposomal doxorubicin in treating patients who have recurrent o... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/23/2015
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +90 locations
Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients
NCT00334321
Completed
This study is evaluating the feasibility of using helical tomotherapy to deliver IMRT in post-hysterectomy endometrial cancer patients receiving adjuvant radiotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/01/2015
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Endometrial Cancer
Register for Updates
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)
NCT01100931
Completed
Background: * Carboplatin-paclitaxel is a commonly used chemotherapy combination for advanced non-small-cell lung carcinoma (NSCLC) and other solid tumors. In a randomized clinical trial, the combination of carboplatin, paclitaxel, and the additional chemotherapy drug bevacizumab had a better response rate and survival compared to carboplatin and paclitaxel alone. However, this trial treated only patients with a specific diagnosis and treatment risks. Further research is needed to determine whe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/29/2015
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: NSCLC, Solid Tumors
Register for Updates
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT00110019
Completed
This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to see how well they work compared to carboplatin and paclitaxel in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate may stop the growth of tumor cells by blocking some... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2015
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +218 locations
Conditions: Mucosal Melanoma, Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Register for Updates
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
NCT00850577
Terminated
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2015
Locations: Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona +54 locations
Conditions: Non-small Cell Lung Cancer (NSCLC)
Register for Updates
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
NCT00002854
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients who have advanced cancer.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/24/2015
Locations: City of Hope Comprehensive Cancer Center, Duarte, California
Conditions: Cancer
Register for Updates
A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer
NCT01111942
Terminated
This is a non-randomized open-label investigator initiated pilot study comparing follow-up therapy of advanced head and neck cancer subjects initially treated with triple induction chemotherapy. Subjects will receive surgical treatment or combined chemoradiation therapy based on the subject's apparent clinical response. Spared use of radiation therapy for selective patients who have a complete response to induction chemotherapy could improve well being of this patient population without compromi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2015
Locations: Southern Illinois University School of Medicine, Springfield, Illinois
Conditions: Head and Neck Cancer
Register for Updates
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
NCT00006263
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining carboplatin, temozolomide, and filgrastim in treating patients who have newly diagnosed or recurrent hi... Read More
Gender:
ALL
Ages:
64 years and below
Trial Updated:
08/03/2015
Locations: NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York
Conditions: Brain and Central Nervous System Tumors
Register for Updates